GoodRx Holdings, Inc. $GDRX Shares Bought by EVR Research LP

Key Points

• EVR Research LP increased its ownership in GoodRx Holdings, Inc. by 243.3%, acquiring a total of 1,300,000 shares valued at approximately $5.73 million.
• GoodRx's recent earnings report showed an EPS of $0.09, missing the consensus estimate by $0.01, amidst a 1.2% year-over-year revenue growth.
• Several analysts have recently adjusted their ratings and target prices for GoodRx, with the average target price now set at $5.80, indicating a mix of buy and hold ratings from various analysts.

EVR Research LP increased its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 243.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,300,000 shares of the company's stock after buying an additional 921,337 shares during the period. GoodRx comprises approximately 1.6% of EVR Research LP's holdings, making the stock its 17th largest holding. EVR Research LP owned about 0.34% of GoodRx worth $5,733,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in GoodRx by 3.0% in the first quarter. Vanguard Group Inc. now owns 8,624,872 shares of the company's stock valued at $38,036,000 after purchasing an additional 251,833 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in GoodRx by 22.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock worth $9,264,000 after acquiring an additional 369,553 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in GoodRx by 16.7% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,434,625 shares of the company's stock worth $6,327,000 after acquiring an additional 205,789 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in GoodRx by 303.3% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,061,461 shares of the company's stock worth $4,936,000 after acquiring an additional 798,261 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its holdings in GoodRx by 54.6% in the first quarter. Raymond James Financial Inc. now owns 830,950 shares of the company's stock worth $3,664,000 after acquiring an additional 293,420 shares in the last quarter. Hedge funds and other institutional investors own 63.77% of the company's stock.

Insider Transactions at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total value of $51,249.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.53% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on GDRX. Raymond James Financial downgraded GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday, August 8th. UBS Group lowered their price target on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $6.00 price target on shares of GoodRx in a report on Monday, August 11th. Finally, The Goldman Sachs Group lowered their price target on GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $5.80.

GoodRx Stock Performance

Shares of GoodRx stock traded down $0.01 on Monday, reaching $4.35. 1,569,793 shares of the stock were exchanged, compared to its average volume of 6,098,105. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.75. GoodRx Holdings, Inc. has a twelve month low of $3.31 and a twelve month high of $8.38. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of 43.50, a PEG ratio of 1.90 and a beta of 1.23. The business has a 50 day moving average price of $4.57 and a two-hundred day moving average price of $4.48.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The firm had revenue of $203.07 million for the quarter, compared to analyst estimates of $205.72 million. During the same period last year, the firm earned $0.08 EPS. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. Analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.